Corcept Therapeutics Incorporated Common Stock Earnings Dividend

Corcept Therapeutics Incorporated Common Stock’s revenue jumped 31.74% since last year same period to $256.15Mn in the Q2 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated 55.33% jump in its revenue since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s net profit jumped 19.89% since last year same period to $42.14Mn in the Q2 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated 235.06% jump in its net profits since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s net profit margin fell -8.99% since last year same period to 16.45% in the Q2 2026. On a quarterly growth basis, Corcept Therapeutics Incorporated Common Stock has generated 186.95% jump in its net profit margins since last 3-months.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.04 - a 71.43% jump from last quarter’s estimates.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at -0.04.

Corcept Therapeutics Incorporated Common Stock’s earning per share (EPS) jumped 24.14% since last year same period to 0.36 in the Q2 2026. This indicates that the Corcept Therapeutics Incorporated Common Stock has generated 24.14% annual rate of jump in its earning per share (EPS) in the last 4 quarters.